Abstract:Non‐invasive positive pressure ventilation (NPPV) has been used to treat respiratory distress due to acute cardiogenic pulmonary oedema (ACPE). We performed a systematic review and meta‐analysis update on NPPV for adults presenting with ACPE. To evaluate the safety and effectiveness of NPPV compared to standard medical care (SMC) for adults with ACPE. The primary outcome was hospital mortality. Important secondary outcomes were endotracheal intubation, treatment intolerance, hospital and intensive care unit length of stay, rates of acute myocardial infarction, and adverse event rates. We searched CENTRAL (CRS Web, 20 September 2018), MEDLINE (Ovid, 1946 to 19 September 2018), Embase (Ovid, 1974 to 19 September 2018), CINAHL Plus (EBSCO, 1937 to 19 September 2018), LILACS, WHO ICTRP, and clinicaltrials.gov. We also reviewed reference lists of included studies. We applied no language restrictions. We included blinded or unblinded randomised controlled trials in adults with ACPE. Participants had to be randomised to NPPV (continuous positive airway pressure (CPAP) or bilevel NPPV) plus standard medical care (SMC) compared with SMC alone. Two review authors independently screened and selected articles for inclusion. We extracted data with a standardised data collection form. We evaluated the risks of bias of each study using the Cochrane 'Risk of bias' tool. We assessed evidence quality for each outcome using the GRADE recommendations. We included 24 studies (2664 participants) of adult participants (older than 18 years of age) with respiratory distress due to ACPE, not requiring immediate mechanical ventilation. People with ACPE presented either to an Emergency Department or were inpatients. ACPE treatment was provided in an intensive care or Emergency Department setting. There was a median follow‐up of 13 days for hospital mortality, one day for endotracheal intubation, and three days for acute myocardial infarction. Compared with SMC, NPPV may reduce hospital mortality (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.51 to 0.82; participants = 2484; studies = 21; I 2 = 6%; low quality of evidence) with a number needed to treat for an additional beneficial outcome (NNTB) of 17 (NNTB 12 to 32). NPPV probably reduces endotracheal intubation rates (RR 0.49, 95% CI 0.38 to 0.62; participants = 2449; studies = 20; I 2 = 0%; moderate quality of evidence) with a NNTB of 13 (NNTB 11 to 18). There is probably little or no difference in acute myocardial infarction (AMI) incidence with NPPV compared to SMC for ACPE (RR 1.03, 95% CI 0.91 to 1.16; participants = 1313; studies = 5; I 2 = 0%; moderate quality of evidence). We are uncertain as to whether NPPV increases hospital length of stay (mean difference (MD) −0.31 days, 95% CI −1.23 to 0.61; participants = 1714; studies = 11; I 2 = 55%; very low quality of evidence). Adverse events were generally similar between NPPV and SMC groups, but evidence was of low quality. Our review provides support for continued clinical application of NPPV for ACPE, to improve outcomes such as hospital mortality and intubation rates. NPPV is a safe intervention with similar adverse event rates to SMC alone. Additional research is needed to determine if specific subgroups of people with ACPE have greater benefit of NPPV compared to SMC. Future research should explore the benefit of NPPV for ACPE patients with hypercapnia. A breathing intervention for shortness of breath due to heart failure Background Heart failure is one of the leading causes of hospital admission in the world. People with heart failure often experience shortness of breath and leg swelling. These symptoms may develop over hours to weeks, or rapidly over a few hours. Such rapid deterioration is called acute cardiogenic pulmonary oedema. Providing air under pressure through a face or nose mask can treat shortness of breath. This treatment is called non‐invasive ventilation and its use in heart failure is controversial. Study characteristics Randomised controlled studies compare treatments to find out if they are truly effective. We searched for randomised studies comparing non‐invasive ventilation to routine care for adults with acute cardiogenic pulmonary oedema. We compared studies treating people with non‐invasive ventilation versus medical care. Medical care includes therapies such as providing extra oxygen and water pills to patients. The evidence upon which this review is based is current to September 2018. Review question We sought to address if non‐invasive ventilation in adults with acute cardiogenic pulmonary oedema reduces rates of deaths, the need for a breathing tube, and heart attacks. Key results and quality of evidence We found 24 studies with 2664 participants comparing non‐invasive ventilation to medical care alone. Non‐invasive ventilation may decrease the chances -Abstract Truncated-

Non-Invasive Ventilation as a Therapy Option for Acute Exacerbations of Chronic Obstructive Pulmonary Disease and Acute Cardiopulmonary Oedema in Emergency Medical Services

The use of noninvasive ventilation in the treatment of acute cardiogenic pulmonary edema

A real life evaluation of non invasive ventilation in acute cardiogenic pulmonary edema: a multicenter, perspective, observational study for the ACPE SIMEU study group

Non-invasive Positive Pressure Ventilation for Acute Cardiogenic Pulmonary Edema and Chronic Obstructive Pulmonary Disease in Prehospital and Emergency Settings

Clinical practice of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease

[Non-invasive Mechanical Ventilation in Acute Respiratory Failure. Clinical Practice Guidelines - on behalf of the German Society of Pneumology and Ventilatory Medicine]

Acute COPD exacerbation treatment with noninvasive ventilation

Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema.

Early non-invasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia

Pathophysiological Basis of Acute Respiratory Failure on Non-Invasive Mechanical Ventilation

Non-invasive ventilation in acute respiratory failure

Role of Non-invasive Ventilation (NIV) in Managing Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review

Meta-analysis: Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema

Noninvasive Ventilation in Critically Ill Patients With Severe Acute Respiratory Infections

Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update

A Multicenter RCT of Noninvasive Ventilation in Pneumonia-Induced Early Mild Acute Respiratory Distress Syndrome

Use of Non-Invasive Positive Pressure Ventilation in Treatment of Refractory Hypoxemia Caused by Acute Pulmonary Edema

High-Flow Nasal Cannula in Early Emergency Department Management of Acute Hypercapnic Respiratory Failure Due to Cardiogenic Pulmonary Edema

High-flow nasal cannula oxygen versus noninvasive ventilation for the management of acute cardiogenic pulmonary edema: a randomized controlled pilot study

Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema – a systematic review and meta-analysis

Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders